People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical trial finds

Oral anticoagulant therapy lowered the hazard of adverse objective events compared with nary anticoagulation successful patients with atrial fibrillation astatine intermediate changeable risk, according to results from the SINGLE-AF proceedings presented successful a Hot Line league astatine ESC Congress 2026 and published simultaneously successful the New England Journal of Medicine.